Vantage logo

No buyout for Uniqure

But a licensing deal with CSL could have underappreciated benefits, even if expectations were for something much bigger.

Vantage logo

The big cap empire strikes back

If the first three quarters of 2019 were dominated by pricing fears, the last saw a remarkable comeback for biopharma.